These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 29045894)

  • 1. From Oncogene Interference to Neutrophil Immune Modulation.
    Bronte V
    Immunity; 2017 Oct; 47(4):613-615. PubMed ID: 29045894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy.
    Glodde N; Bald T; van den Boorn-Konijnenberg D; Nakamura K; O'Donnell JS; Szczepanski S; Brandes M; Eickhoff S; Das I; Shridhar N; Hinze D; Rogava M; van der Sluis TC; Ruotsalainen JJ; Gaffal E; Landsberg J; Ludwig KU; Wilhelm C; Riek-Burchardt M; Müller AJ; Gebhardt C; Scolyer RA; Long GV; Janzen V; Teng MWL; Kastenmüller W; Mazzone M; Smyth MJ; Tüting T; Hölzel M
    Immunity; 2017 Oct; 47(4):789-802.e9. PubMed ID: 29045907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MET Oncogene Targeting for Cancer Immunotherapy.
    Lombardi AM; Sangiolo D; Vigna E
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the MET oncogene in cancer and metastases.
    Stella GM; Benvenuti S; Comoglio PM
    Expert Opin Investig Drugs; 2010 Nov; 19(11):1381-94. PubMed ID: 20868306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy.
    Comoglio PM; Trusolino L; Boccaccio C
    Nat Rev Cancer; 2018 Jun; 18(6):341-358. PubMed ID: 29674709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells.
    Comoglio PM
    EXS; 1993; 65():131-65. PubMed ID: 8380735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug development of MET inhibitors: targeting oncogene addiction and expedience.
    Comoglio PM; Giordano S; Trusolino L
    Nat Rev Drug Discov; 2008 Jun; 7(6):504-16. PubMed ID: 18511928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Only a subset of Met-activated pathways are required to sustain oncogene addiction.
    Bertotti A; Burbridge MF; Gastaldi S; Galimi F; Torti D; Medico E; Giordano S; Corso S; Rolland-Valognes G; Lockhart BP; Hickman JA; Comoglio PM; Trusolino L
    Sci Signal; 2009 Dec; 2(100):ra80. PubMed ID: 19996456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion.
    Lorenzato A; Olivero M; Patanè S; Rosso E; Oliaro A; Comoglio PM; Di Renzo MF
    Cancer Res; 2002 Dec; 62(23):7025-30. PubMed ID: 12460923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ron kinase transphosphorylation sustains MET oncogene addiction.
    Benvenuti S; Lazzari L; Arnesano A; Li Chiavi G; Gentile A; Comoglio PM
    Cancer Res; 2011 Mar; 71(5):1945-55. PubMed ID: 21212418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel mutations of the MET proto-oncogene in papillary renal carcinomas.
    Schmidt L; Junker K; Nakaigawa N; Kinjerski T; Weirich G; Miller M; Lubensky I; Neumann HP; Brauch H; Decker J; Vocke C; Brown JA; Jenkins R; Richard S; Bergerheim U; Gerrard B; Dean M; Linehan WM; Zbar B
    Oncogene; 1999 Apr; 18(14):2343-50. PubMed ID: 10327054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy.
    Reis H; Metzenmacher M; Goetz M; Savvidou N; Darwiche K; Aigner C; Herold T; Eberhardt WE; Skiba C; Hense J; Virchow I; Westerwick D; Bogner S; Ting S; Kasper S; Stuschke M; Nensa F; Herrmann K; Hager T; Schmid KW; Schuler M; Wiesweg M
    Clin Lung Cancer; 2018 Jul; 19(4):e441-e463. PubMed ID: 29631966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene of the month: MET.
    Skead G; Govender D
    J Clin Pathol; 2015 Jun; 68(6):405-9. PubMed ID: 25987653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.
    Noonan SA; Berry L; Lu X; Gao D; Barón AE; Chesnut P; Sheren J; Aisner DL; Merrick D; Doebele RC; Varella-Garcia M; Camidge DR
    J Thorac Oncol; 2016 Aug; 11(8):1293-1304. PubMed ID: 27262212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis.
    Bertotti A; Comoglio PM; Trusolino L
    Cancer Res; 2005 Dec; 65(23):10674-9. PubMed ID: 16322210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Correlation of c-met activation with human carcinogrenesis].
    Gao CF; Lu YY
    Sheng Li Ke Xue Jin Zhan; 1995 Jul; 26(3):243-5. PubMed ID: 8584893
    [No Abstract]   [Full Text] [Related]  

  • 17. Oncogenic Met receptor induces cell-cycle progression in Xenopus oocytes independent of direct Grb2 and Shc binding or Mos synthesis, but requires phosphatidylinositol 3-kinase and Raf signaling.
    Mood K; Saucier C; Ishimura A; Bong YS; Lee HS; Park M; Daar IO
    J Cell Physiol; 2006 Apr; 207(1):271-85. PubMed ID: 16331688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of Ron and Met proto-oncogene expression in epithelial ovarian tumors].
    Fracchioli S; Katsaros D; Maggiora P; Di Renzo MF; Massobrio M
    Minerva Ginecol; 1999 Oct; 51(10):359-64. PubMed ID: 10638160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population.
    Lindor NM; Dechet CB; Greene MH; Jenkins RB; Zincke MT; Weaver AL; Wilson M; Zincke H; Liu W
    Genet Test; 2001; 5(2):101-6. PubMed ID: 11551094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF.
    Konda JD; Olivero M; Musiani D; Lamba S; Di Renzo MF
    Mol Oncol; 2017 Jun; 11(6):599-611. PubMed ID: 28182330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.